A Randomized, Double-Blind, Placebo-Controlled Safety and Tolerability Study of Repeated Doses of Anti-IgE Immunotherapy in Allergic Patients
Phase of Trial: Phase II
Latest Information Update: 16 Sep 2014
At a glance
- Drugs RP 01 (Primary)
- Indications Allergic asthma
- Focus Adverse reactions
- Sponsors Resistentia Pharmaceuticals
- 16 Sep 2014 New source identified and integrated (ClinicalTrials.gov record NCT00439621).
- 26 Apr 2007 New trial record.